Johnson & Johnson has weathered the market sell off better than most, but will the quarterly results give investors enough reasons to keep on buying? Keep an eye on two things: Remicade and stents.... Read More
Not too long ago, some had written off the potential for significant growth to resume in sales of the little wire mesh tubes that are painted with special drugs to help keep arteries from reclogging.... Read More